Adjuvant therapy for endometrial cancer

Maria C. DeLeon, Natraj R. Ammakkanavar, Daniela Matei

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with endometrial cancer.

Original languageEnglish
Pages (from-to)136-147
Number of pages12
JournalJournal of Gynecologic Oncology
Volume25
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Endometrial Neoplasms
Uterine Neoplasms
Gynecology
Obstetrics
Therapeutics
Recurrence
Neoplasms

Keywords

  • Adjuvant therapy
  • Early stage
  • Endometrial cancer
  • Locally advanced
  • Risk stratification

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Adjuvant therapy for endometrial cancer. / DeLeon, Maria C.; Ammakkanavar, Natraj R.; Matei, Daniela.

In: Journal of Gynecologic Oncology, Vol. 25, No. 2, 2014, p. 136-147.

Research output: Contribution to journalArticle

DeLeon, Maria C. ; Ammakkanavar, Natraj R. ; Matei, Daniela. / Adjuvant therapy for endometrial cancer. In: Journal of Gynecologic Oncology. 2014 ; Vol. 25, No. 2. pp. 136-147.
@article{6eaac7dfda7c471ab7613b66c7137586,
title = "Adjuvant therapy for endometrial cancer",
abstract = "Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with endometrial cancer.",
keywords = "Adjuvant therapy, Early stage, Endometrial cancer, Locally advanced, Risk stratification",
author = "DeLeon, {Maria C.} and Ammakkanavar, {Natraj R.} and Daniela Matei",
year = "2014",
doi = "10.3802/jgo.2014.25.2.136",
language = "English",
volume = "25",
pages = "136--147",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "2",

}

TY - JOUR

T1 - Adjuvant therapy for endometrial cancer

AU - DeLeon, Maria C.

AU - Ammakkanavar, Natraj R.

AU - Matei, Daniela

PY - 2014

Y1 - 2014

N2 - Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with endometrial cancer.

AB - Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with endometrial cancer.

KW - Adjuvant therapy

KW - Early stage

KW - Endometrial cancer

KW - Locally advanced

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=84899156103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899156103&partnerID=8YFLogxK

U2 - 10.3802/jgo.2014.25.2.136

DO - 10.3802/jgo.2014.25.2.136

M3 - Article

AN - SCOPUS:84899156103

VL - 25

SP - 136

EP - 147

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 2

ER -